Analysis of urinary nucleosides as potential tumor markers in human breast cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry

Clinica Chimica Acta

Volumn 412, Issue 19-20, 2011, Pages 1861-1866

  Hsu, Wei Yi ^a   Lin, Wei De ^a   Tsai, Yuhsin ^b   Lin, Chiung Tsung ^a   Wang, Hwei Chung ^a   Jeng, Long Bin ^a   Lee, Ching Chih ^a   Lin, Yu Chiang ^a   Lai, Chien Chen ^b,c   Tsai, Fuu Jen ^a,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; HPLC MS MS; Nucleosides; Tumor markers; Urine

Indexed keywords

1 METHYLADENOSINE; 2 DEOXYGUANOSINE; 2 DEOXYNUCLEOSIDE; 3 METHYLCYTIDINE; 8 HYDROXYDEOXYGUANOSINE; ADENOSINE; BENZENEBORONIC ACID; CYTIDINE; GUANOSINE; INOSINE; N2,N2 DIMETHYLGUANINE; NUCLEOSIDE; NUCLEOSIDE DERIVATIVE; TUBERCIDIN; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; CATION EXCHANGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; RETENTION TIME; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY; URINE LEVEL;

CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; NUCLEOSIDES; REFERENCE STANDARDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79960651478     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.027     Document Type: Article

References (31)

1. Bond A., Dudley E., Lemiere F., et al. Analysis of urinary nucleosides. V. Identification of urinary pyrimidine nucleosides by liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 2006, 20:137-150.
2. Dudley E., Lemiere F., Van Dongen W., et al. Analysis of urinary nucleosides. IV. Identification of urinary purine nucleosides by liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 2004, 18:2730-2738.
3. Li H.Y., Wang S.M., Liu H.M., et al. Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom 2009, 44:641-651.
4. Gehrke C.W., Kuo K.C., Waalkes T.P., Borek E. Patterns of urinary excretion of modified nucleosides. Cancer Res 1979, 39:1150-1153.
5. Speer J., Gehrke C.W., Kuo K.C., Waalkes T.P., Borek E. tRNA breakdown products as markers for cancer. Cancer 1979, 44:2120-2123.
6. Nakano K., Nakao T., Schram K.H., et al. Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS. Clin Chim Acta 1993, 218:169-183.
7. Gehrke C.W., Kuo K.C. Ribonucleoside analysis by reversed-phase high-performance liquid chromatography. J Chromatogr 1989, 471:3-36.
8. Simionato A.V., Carrilho E., Maggi Tavares M.F. CE-MS and related techniques as a valuable tool in tumor biomarkers research. Electrophoresis 2010, 31:1214-1226.
9. Sova H., Jukkola-Vuorinen A., Puistola U., Kauppila S., Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer 2010, 102:1018-1023.
10. Cho S.H., Choi M.H., Lee W.Y., Chung B.C. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clin Biochem 2009, 42:540-543.
11. Cho S.H., Jung B.H., Lee S.H., Lee W.Y., Kong G., Chung B.C. Direct determination of nucleosides in the urine of patients with breast cancer using column-switching liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2006, 20:1229-1236.
12. Marvel C.C., Del Rowe J., Bremer E.G., Moskal J.R. Altered RNA turnover in carcinogenesis. The diagnostic potential of modified base excretion. Mol Chem Neuropathol 1994, 21:353-368.
13. Bartels H., Bohmer M., Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta 1972, 37:193-197.
14. Seidel A., Brunner S., Seidel P., Fritz G.I., Herbarth O. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. Br J Cancer 2006, 94:1726-1733.
15. Zheng Y.F., Kong H.W., Xiong J.H., Lv S., Xu G.W. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin Biochem 2005, 38:24-30.
16. Zheng Y.F., Xu G.W., Liu D.Y., et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography. Electrophoresis 2002, 23:4104-4109.
17. Feng B., Zheng M.H., Zheng Y.F., et al. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. J Gastroenterol Hepatol 2005, 20:1913-1919.
18. Hall R.H. Isolation of 3-methyluridine and 3-methylcytidine from solubleribonucleic acid. Biochem Biophys Res Commun 1963, 12:361-364.
19. Iwanami Y., Brown G.M. Methylated bases of ribosomal ribonucleic acid from HeLa cells. Arch Biochem Biophys 1968, 126:8-15.
20. Iwanami Y., Brown G.M. Methylated bases of transfer ribonucleic acid from HeLa and L cells. Arch Biochem Biophys 1968, 124:472-482.
21. Leiros I., Nabong M.P., Grosvik K., et al. Structural basis for enzymatic excision of N1-methyladenine and N3-methylcytosine from DNA. EMBO J 2007, 26:2206-2217.
22. Delaney J.C., Essigmann J.M. Mutagenesis, genotoxicity, and repair of 1-methyladenine, 3-alkylcytosines, 1-methylguanine, and 3-methylthymine in alkB Escherichia coli. Proc Natl Acad Sci USA 2004, 101:14051-14056.
23. Feinberg A.P., Gehrke C.W., Kuo K.C., Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988, 48:1159-1161.
24. Zuo S., Boorstein R.J., Teebor G.W. Oxidative damage to 5-methylcytosine in DNA. Nucleic Acids Res 1995, 23:3239-3243.
25. Barciszewska A.M., Murawa D., Gawronska I., Murawa P., Nowak S., Barciszewska M.Z. Analysis of 5-methylcytosine in DNA of breast and colon cancer tissues. IUBMB Life 2007, 59:765-770.
26. Sasco A.J., Rey F., Reynaud C., Bobin J.Y., Clavel M., Niveleau A. Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Lett 1996, 108:157-162.
27. Kammerer B., Frickenschmidt A., Muller C.E., Laufer S., Gleiter C.H., Liebich H. Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. Anal Bioanal Chem 2005, 382:1017-1026.
28. Jensen S.S., Ariza X., Nielsen P., Vilarrasa J., Kirpekar F. Collision-induced dissociation of cytidine and its derivatives. J Mass Spectrom 2007, 42:49-57.
29. Xu G., Schmid H.R., Lu X., Liebich H.M., Lu P. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed Chromatogr 2000, 14:459-463.
30. Bullinger D., Frohlich H., Klaus F., et al. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal Chim Acta 2008, 618:29-34.
31. Cho J., Kim J., Kim K. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal Chim Acta 2003, 486:171-182.